April 2024

New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year DUBLIN and ATLANTA, April 7, 2024 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthca

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: